This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Anne De Groot, MD
Founder, CEO and CSO at EpiVax, Inc.


Dr. Anne De Groot is internationally known for her research on the human immune system’s response to vaccines and therapeutics. She graduated from Smith College in 1978 and earned her medical degree at the University of Chicago in 1983. After an internal medicine residency, she obtained advanced training in immunoinformatics and vaccinology with Michael Good, Russell Howard and Jay Berzofsky at the National Institutes of Health, and then returned for a fellowship in ID at New England Medical Center. De Groot joined the faculty of Brown University in 1993, establishing the TB/HIV Research Lab as an emerging center for immune informatics-driven vaccine design. In 2008, she moved her academic affiliation to the University of Rhode Island, where she serves as director of the Institute for Immunology and Informatics (iCubed).

De Groot is the co-founder and CEO/CSO of EpiVax, Inc., a leading company in the field of immunoinformatics, working with a wide range of global clients and partners to improve the design of vaccines and biologics and improving human health everywhere. EpiVax will celebrate its 20th anniversary in 2018. De Groot has been the recipient of many awards for her groundbreaking work at the intersection of immunology and informatics and is recognized as an early adopter of this technology and an evangelist for the use of immunoinformatics to improve vaccines and protein therapeutics.

Agenda Sessions

  • Chairperson's Remarks

  • Screen for Immunogenicity? What Does that Mean! An Expert’s Guide to Immunogenicity Screening for Peptide Drugs